|
Pancreatic carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A prior site of disease (including intracranial metastases) was HER2+ for 13% of evaluable patients: 3 of 11 patients with colorectal cancer and no patients with esophageal or pancreatic cancer.
|
30373904 |
2019 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Background Studies suggest that bevacizumab-induced hypertension is prognostic of better outcomes in bevacizumab-treated patients with metastatic colorectal, HER2-negative breast, kidney, and pancreatic cancer.
|
29284349 |
2018 |
|
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
By immunohistochemical analysis in human cases, HER2 protein expression was detected in 40% of PDAs and 29% of intraductal papillary mucinous carcinomas, another type of pancreatic cancer.
|
29670173 |
2018 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mutation (Kras, ERBB2-exon17 and KrasG12V), circulating tumor DNA (ctDNA) presence, hypermethylation and higher concentration of cfDNA were both associated with worse survival results in pancreatic cancer.
|
30227250 |
2018 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results demonstrated that in Fcγ-RIIIA-VV/VF-carrying healthy individuals, trastuzumab plus αCD137 mAb could induce effective ADCC against HER2-low-expressing pancreatic cancer cell lines, and that such an approach may result in similar findings in patients with pancreatic cancer.
|
30596643 |
2018 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previous studies have shown that human epidermal growth factor receptor 2 (HER2) may play an important role in the invasion and metastasis of pancreatic cancer, but the relationship between HER2 amplification level and prognosis of pancreatic cancer patients is still controversial.
|
26897036 |
2016 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model.
|
27267807 |
2016 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Besides, we and others have demonstrated de novo expression of MUC4 in ~70-90% of pancreatic cancer patients and its stabilizing effects on HER2 downstream signaling in pancreatic cancer.
|
25686822 |
2015 |
|
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aims of this study were to investigate expression of HER-1, HER-2 and HER-3 in pancreatic cancer (PC) samples and evaluate the association between HER-family receptor expression and patients' clinical outcomes.
|
26109364 |
2015 |
|
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, we demonstrated that nicotine-mediated MUC4 upregulation promotes the PC cell migration through the activation of the downstream effectors, such as HER2, c-Src and FAK; this effect was attenuated by shRNA-mediated MUC4 abrogation, further implying that these nicotine-mediated pathological effects on PC cells are MUC4 dependent.
|
22614008 |
2013 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Frequent outlier kinases in breast cancer included therapeutic targets like ERBB2 and FGFR4, distinct from MET, AKT2, and PLK2 in pancreatic cancer.
|
23384775 |
2013 |
|
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Because of co-activation of these two signaling pathways, we assessed the efficacy of inhibition of EGFR/HER2 receptors and the downstream KRAS effector, mitogen-activated protein kinase/extracellular-signal regulated kinase (ERK) kinase 1 and 2 (MEK1/2), on pancreatic cancer proliferation in vitro and in a murine orthotopic xenograft model.
|
23441129 |
2013 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This multicentre phase II study investigated the efficacy and toxicity of the HER2 antibody trastuzumab combined with capecitabine in the patients with pancreatic cancer and HER2 overexpression.
|
22374460 |
2012 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer.
|
22589274 |
2012 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Enhanced pancreatic cancer gene therapy by combination of adenoviral vector expressing c-erb-B2 (Her-2/neu)-targeted immunotoxin with a replication-competent adenovirus or etoposide.
|
19751100 |
2010 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated the effects of inhibition of EGFR/HER2 signaling on pancreatic cancer to elucidate the role(s) of EGFR/HER2 in radiosensitization and to provide evidence in support of further clinical investigations.
|
20103665 |
2010 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These encouraging results support future clinical trials using this chimera vaccine and may be applicable to other cancer types expressing the Her-2/neu molecule such as colorectal and pancreatic cancer.
|
19188163 |
2009 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
More importantly, we show that this nanoimmunoliposome anti-HER-2 siRNA complex can sensitize human tumor cells to chemotherapeutics, silence the target gene and affect its downstream pathway components in vivo, and significantly inhibit tumor growth in a pancreatic cancer model.
|
17409398 |
2007 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, this study showed that combination therapy with trastuzumab and S-1 may be effective for HER2-overexpressing pancreatic cancer patients.
|
17611667 |
2007 |
|
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In contrast, the growth factor receptor genes c-erbB-1 and c-erbB-2 are differentially regulated in both tumor entities adding further evidence that pancreatic cancer is biologically different from the cancer of papilla of Vater.
|
16489645 |
2006 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Infrequent HER-2/neu overexpression limits the role of targeting the HER-2/neu gene and prevents definitive conclusions on the addition of Herceptin to gemcibine for patients with pancreatic cancer.
|
15581051 |
2004 |
|
Pancreatic carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, these PanIN-like lesions also contain mutations in K-ras and overexpress HER-2/neu, which are genetic mutations found early in the progression of human pancreatic cancer.
|
14520413 |
2003 |
|
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data demonstrate that overexpression of p21(WAF1/CIP1) occurs early in the development of PanIN, before aberrations in p53, cyclin D1, and DPC4/Smad4 expression. p21(WAF1/CIP1) overexpression, independent of p53 and/or DPC4/Smad4 expression, may reflect increased Ras activity, either directly through activating K-ras mutations or as a consequence of HER-2/neu (ERBB2) overexpression, both of which are common in PC and in early events in the development of PanIN.
|
11751405 |
2001 |
|
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HER-2/neu overexpression occurs in a subset of pancreatic cancer.
|
11586103 |
2001 |
|
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
C-erbB-2 overexpression in pancreatic cancer vary widely between 17 to 82%.
|
11583287 |
2001 |